Move to topTop
December 13, 2017

TOKYO, JAPAN - December 13, 2017 - Terumo Corporation (TSE: 4543) today announced that it will construct a new building for manufacturing interventional systems products on the property of Terumo Yamaguchi Corporation. Terumo will hire approximately 700 associates and invest a total of approximately 30 billion yen in the facility. Construction work is scheduled for June 2018 to October 2019, and operations are scheduled to commence in April 2021.

Terumo Yamaguchi manufactures access guidewires used in interventional procedures. The new building will be the company's third such structure. The company plans to increase the number of guidewire products it produces, as well as its total production capacity. The area of the new building will be approximately 50,000 square meters, or over three times the size of the site's first building, which currently manufactures guidewires.

Terumo has "Strengthen Global Operations" as one of key initiatives towards sustainable growth. The new building will strengthen production capacity in a growing field and optimize production on a global and group basis. The Terumo Interventional Systems Division leads Terumo group in revenue growth, and the construction is expected to support business growth in the globally growing interventional market.

As a global corporation with unique excellence, Terumo aims to become a top brand trusted in medical settings all over the world, through providing "Total Quality": high quality in all aspects of product, supply, and service.

20171213.jpg

About Terumo

Terumo (TSE: 4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for 100 years. Based in Tokyo and operating globally, Terumo employs more than 28,000 associates worldwide to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese thermometer manufacturer, and has been supporting healthcare ever since. Now, its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice such as transfusion systems, diabetes care, and peritoneal dialysis treatments. Terumo will further strive to be of value to patients, medical professionals, and society at large.

Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

 

Information about products (including products currently in development) included in this material is not intended to constitute an advertisement or medical advice.